All In Biotech

Drug Trial Radar · NCT07933783

An Open-label Study With Maintenance Dosing of ORKA-002 in Participants With Moderate-to-Severe Plaque Psoriasis

An Open-label Study With Maintenance Dosing to Evaluate the Long-term Safety, Tolerability, and Efficacy of ORKA-002 in Participants With Moderate-to-Severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

160

Planned (sponsor's estimate)

Start

Oct 26, 2026

Primary completion

Jul 1, 2029

Study completion Sep 1, 2029

Sponsor

Lead sponsor
Oruka Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Nov 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open-label study with maintenance dosing to evaluate the long-term safety and efficacy of ORKA-002 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.

Conditions

  • Plaque Psoriasis

Interventions

  • ORKA-002Drug

    ORKA-002 administered by subcutaneous (SC) injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and TEAEs of Special Interest (TEAESIs)Time frame: Day 1 through Week 144

Locations

8 sites in 2 countries. Site status is shown where the registry gives one.

  • Oruka Therapeutics Investigative Site

    Fountain Valley, California

  • Oruka Therapeutics Investigative Site

    Milford, Massachusetts

  • Oruka Therapeutics Investigative Site

    New Brighton, Minnesota

  • Oruka Therapeutics Investigative Site

    Wilmington, North Carolina

  • Oruka Therapeutics Investigative Site

    Warrenton, Oregon

  • Oruka Therapeutics Investigative Site

    Barrie, Ontario, Canada

  • Oruka Therapeutics Investigative Site

    North Bay, Ontario, Canada

  • Oruka Therapeutics Investigative Site

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.